Kazia Therapeutics Limited – NASDAQ:KZIA

Kazia Therapeutics Limited stock price today

$7.32
+4.25
+138.44%
Financial Health
0
1
2
3
4
5
6
7
8
9

Kazia Therapeutics Limited stock price monthly change

+242.71%
month

Kazia Therapeutics Limited stock price quarterly change

+242.71%
quarter

Kazia Therapeutics Limited stock price yearly change

+613.95%
year

Kazia Therapeutics Limited key metrics

Market Cap
10.15M
Enterprise value
12.15M
P/E
-0.95
EV/Sales
1.88
EV/EBITDA
-0.95
Price/Sales
3.27
Price/Book
1.82
PEG ratio
N/A
EPS
-2.25
Revenue
N/A
EBITDA
-38.59M
Income
-37.79M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-200.35%
Oper. margin
-557.32%
Gross margin
0.01%
EBIT margin
-557.32%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Kazia Therapeutics Limited stock price history

Kazia Therapeutics Limited stock forecast

Kazia Therapeutics Limited financial statements

Kazia Therapeutics Limited (NASDAQ:KZIA): Profit margin
Dec 2021 10K -13.20M -132018.48%
Mar 2022 0 -5.90M
Jun 2022 0 -11.81M
Jun 2023 555 -6.87M -1239487.03%
Kazia Therapeutics Limited (NASDAQ:KZIA): Analyst Estimates
2026 2.70M -916.69K -33.91%
2027 24.17M 0
  • Analysts Price target

  • Financials & Ratios estimates

Kazia Therapeutics Limited (NASDAQ:KZIA): Debt to assets
Jun 2022 -22761 -25.01K 109.91%
Sep 2022 0 0
Dec 2022 27835603 16.25M 58.39%
Jun 2023 28085177 16.03M 57.09%
Kazia Therapeutics Limited (NASDAQ:KZIA): Cash Flow
Dec 2021 -11.39M -278 16.7K
Mar 2022 -5.68M -391.22K 1.85M
Jun 2022 -11.37M -782.45K 3.70M
Jun 2023 -6.35M -5.24M 7.12M

Kazia Therapeutics Limited alternative data

Kazia Therapeutics Limited (NASDAQ:KZIA): Employee count
Mar 2024 9
Apr 2024 9
May 2024 9
Jun 2024 9
Jul 2024 9

Kazia Therapeutics Limited other data

0.05% -0.27%
of KZIA is owned by hedge funds
69.01K -357.13K
shares is hold by hedge funds

Kazia Therapeutics Limited (NASDAQ:KZIA): Insider trades (number of shares)
Period Buy Sel
Feb 2013 0 3500
Oct 2013 0 191125
Nov 2013 0 49322
Transaction Date Insider Security Shares Price per share Total value Source
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 23,922 $6.01 $143,699
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 25,400 $6.03 $153,035
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 1,100 $6.04 $6,641
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 37,409 $6.18 $231,225
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 62,591 $6.17 $386,312
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 90,025 $6.21 $559,235
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 500 $8 $4,000
Sale
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 25 ordinary shares 3,000 $8 $24,000
Purchase
AUSTIN JOSIAH T 10 percent owner
Sponsored Ordinary shares 4,531,633 $1.16 $5,256,694
Purchase
AUSTIN JOSIAH T 10 percent owner
Sponsored ADRs, each convertible into 5 ordinary shares 7,000 $4.9 $34,279
Insider Compensation
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( (1973) Chief Executive Officer, MD & Executive Director
$650,330
Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD (1959) Company Sec.
$97,060
Wednesday, 11 December 2024
prnewswire.com
Monday, 4 November 2024
prnewswire.com
Wednesday, 2 October 2024
prnewswire.com
Monday, 23 September 2024
prnewswire.com
Thursday, 12 September 2024
prnewswire.com
Wednesday, 31 July 2024
investorplace.com
Thursday, 25 July 2024
investorplace.com
Friday, 12 July 2024
zacks.com
investorplace.com
Thursday, 11 July 2024
investorplace.com
marketwatch.com
Wednesday, 10 July 2024
benzinga.com
investorplace.com
prnewswire.com
Thursday, 27 June 2024
prnewswire.com
Thursday, 23 May 2024
prnewswire.com
Wednesday, 1 May 2024
prnewswire.com
Thursday, 21 March 2024
prnewswire.com
Wednesday, 13 March 2024
prnewswire.com
Wednesday, 21 February 2024
prnewswire.com
Thursday, 18 January 2024
prnewswire.com
Tuesday, 5 December 2023
prnewswire.com
Friday, 1 December 2023
prnewswire.com
Wednesday, 29 November 2023
prnewswire.com
Tuesday, 21 November 2023
prnewswire.com
Monday, 20 November 2023
prnewswire.com
Wednesday, 15 November 2023
prnewswire.com
Friday, 10 November 2023
prnewswire.com
Wednesday, 1 November 2023
prnewswire.com
Monday, 23 October 2023
prnewswire.com
  • What's the price of Kazia Therapeutics Limited stock today?

    One share of Kazia Therapeutics Limited stock can currently be purchased for approximately $7.32.

  • When is Kazia Therapeutics Limited's next earnings date?

    Unfortunately, Kazia Therapeutics Limited's (KZIA) next earnings date is currently unknown.

  • Does Kazia Therapeutics Limited pay dividends?

    No, Kazia Therapeutics Limited does not pay dividends.

  • How much money does Kazia Therapeutics Limited make?

    Kazia Therapeutics Limited has a market capitalization of 10.15M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 415755.86% to 2.31M US dollars.

  • What is Kazia Therapeutics Limited's stock symbol?

    Kazia Therapeutics Limited is traded on the NASDAQ under the ticker symbol "KZIA".

  • What is Kazia Therapeutics Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Kazia Therapeutics Limited?

    Shares of Kazia Therapeutics Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Kazia Therapeutics Limited's key executives?

    Kazia Therapeutics Limited's management team includes the following people:

    • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( Chief Executive Officer, MD & Executive Director(age: 52, pay: $650,330)
    • Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD Company Sec.(age: 66, pay: $97,060)
  • How many employees does Kazia Therapeutics Limited have?

    As Jul 2024, Kazia Therapeutics Limited employs 9 workers.

  • When Kazia Therapeutics Limited went public?

    Kazia Therapeutics Limited is publicly traded company for more then 26 years since IPO on 6 Jan 1999.

  • What is Kazia Therapeutics Limited's official website?

    The official website for Kazia Therapeutics Limited is kaziatherapeutics.com.

  • Where are Kazia Therapeutics Limited's headquarters?

    Kazia Therapeutics Limited is headquartered at Three International Towers, Sydney, NSW.

  • How can i contact Kazia Therapeutics Limited?

    Kazia Therapeutics Limited's mailing address is Three International Towers, Sydney, NSW and company can be reached via phone at +1 300787272.

Kazia Therapeutics Limited company profile:

Kazia Therapeutics Limited

kaziatherapeutics.com
Exchange:

NASDAQ

Full time employees:

9

Industry:

Biotechnology

Sector:

Healthcare

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Three International Towers
Sydney, NSW 2000

CIK: 0001075880
ISIN: US48669G1058
CUSIP: 48669G105